Online inquiry

IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11552MR)

This product GTTS-WQ11552MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD3E gene. The antibody can be applied in Type 1 diabetes research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000733.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916
UniProt ID P07766
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ11552MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12145MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-004
GTTS-WQ11667MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ5688MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ15958MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ8012MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GZ-402668
GTTS-WQ8493MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA hu1124
GTTS-WQ1361MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-874
GTTS-WQ11226MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI3902
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW